US Physical Therapy’s Earnings Swing Signals a Tipping Point

Volatile cash flow and rising costs could reshape the clinic operator’s outlook

USPH U.S. Physical Therapy, Inc.

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

USPH — U.S. Physical Therapy, Inc.

Healthcare · Medical - Care Facilities $940.07M · Small Cap B2C/B2B

Business & Competitive Position

💰 Revenue Model Services

🏗️ Asset Profile Asset-Heavy

🛡️ Economic Moat

No Moat (Commodity)

🔒 Unknown

📈 Pricing Power

Strong

🏆 Market Position Competitor

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue +16.3% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

78.7x P/E 2.5x P/B 14.4x EV/EBITDA 2.31% Div

⚖️ Tier

Fair Value

📊 Beta 1.20 (Moderate Volatility)

U.S. Physical Therapy, Inc. (USPH) operates a nationwide network of outpatient physical therapy clinics that deliver reimbursable, fee‑for‑service care to both individual patients and employer‑sponsored health plans. The business has leveraged its asset‑heavy footprint to capture a 16.3% YoY revenue increase to $781 million, while maintaining an operating margin of 10.3%, reflecting disciplined cost control in a largely commoditized market. Strong pricing power—evidenced by the ability to sustain margins despite a high P/E of 78.7x—helps offset modest net profitability (1.9%). As a defensive, moderate‑growth player with a beta of 1.20, USPH offers exposure to stable healthcare demand while delivering upside potential from continued outpatient volume expansion.

Revenue growth outpaces the broader medical‑care facilities sector, driven by strategic clinic acquisitions and higher utilization rates, positioning USPH for scalable top‑line expansion.
Operating efficiency remains a core advantage; a 10.3% operating margin in an asset‑heavy, low‑moat business indicates effective labor management and favorable payer contracts.
Pricing power is unusually robust for a commodity service provider, allowing the company to command premium rates that support elevated valuation multiples despite modest net margins.
Defensive demand dynamics—stemming from aging demographics and increasing musculoskeletal injury prevalence—provide a stable revenue base, while a beta of 1.20 suggests upside participation in broader market rallies.

Equity Performance & Market Positioning

U.S. Physical Therapy, Inc. (USPH) — Stock Returns

Recent Performance

-13.8%

1 Month

vs S&P -14.1

-21.8%

3 Month

vs S&P -31.3

-15.9%

6 Month

vs S&P -23.7

-18.7%

YTD

vs S&P -26.6

-14.7%

1 Year

vs S&P -38.3

USPH fell 13.8% over the past month, marginally outperforming the S&P 500's 14.1% decline, indicating relative resilience in a weak market environment.
The three‑month drop of 21.8% versus the index's 31.3% suggests USPH's earnings visibility or sector positioning may be cushioning it against broader equity sell‑offs.
Six‑month performance shows a -15.9% decline, still better than the S&P's -23.7%, highlighting that the stock has maintained a tighter downside trajectory despite macro volatility.
Year‑to‑date loss of 18.7% trails the index by roughly 8 percentage points, reinforcing a pattern of outperformance that could attract value‑oriented investors seeking relative strength.

Long-Term Performance (Annualized)

-13.6%

3 Year

vs S&P -34.1

-10.2%

5 Year

vs S&P -22.1

2.2%

10 Year

vs S&P -11.2

11.5%

Full History

vs S&P +3.4

Over the past three years, USPH delivered an annualized return of -13.6%, halving the S&P's -34.1% loss, reflecting a business model that is less sensitive to economic cycles.
The five‑year annualized decline of -10.2% versus the index's -22.1% underscores USPH's ability to generate modest growth or preserve capital in a sector with steady demand for physical therapy services.
A 10‑year annualized gain of +2.2% contrasts sharply with the S&P's -11.2% drop, indicating that the company's long‑term trajectory has turned positive despite short‑term headwinds.
Across its full trading history, USPH outperformed the market by 8.1 percentage points annually (11.5% vs 3.4%), suggesting a durable competitive advantage in an aging U.S. population.

Highlight

USPH's consistent outperformance across all recent horizons (e.g., -13.8% vs -14.1% MTD and -21.8% vs -31.3% QTD) signals a defensive bias that may make it a preferred holding during equity market corrections.

Watch Out

The three‑year and five‑year negative annualized returns (-13.6% and -10.2%) reveal that USPH remains vulnerable to reimbursement pressure and payer consolidation; a further 5% reduction in average reimbursement rates could push multi‑year performance into double‑digit declines, eroding its long‑term outperformance edge.

Equity Performance & Market Positioning

U.S. Physical Therapy, Inc. (USPH) — Risk & Smart Money

Risk Profile

44.8%

Volatility (20D)

1.16

Beta

-0.43

Sharpe Ratio

-36.7%

Max Drawdown (1Y)

52

RSI (14)

15%

52-Week Range

The 44.8% annualized volatility far exceeds the S&P 500 average (~15%), indicating USPH price swings are roughly three times larger and can erode investor confidence during market stress.
A beta of 1.2 shows the stock moves 20% more than the broader market, amplifying downside risk when equities tumble but also offering upside in bull markets.
The negative Sharpe ratio (-0.4) signals that recent returns have not compensated for the high volatility, implying poor risk‑adjusted performance relative to a risk‑free rate.
A maximum drawdown of -36.7% reflects a deep historical trough, suggesting that investors could lose over a third of their capital in a prolonged downturn.
RSI at 52.2 places USPH near the neutral zone, indicating no strong momentum bias but also that price is not currently oversold enough to attract contrarian buying.

Smart Money Positioning

105.8%

Institutional Ownership

+0.5% QoQ

1.27

Insider Buy/Sell

Institutional ownership stands at 105.79%, reflecting significant long‑only and index fund holdings that view USPH as a core exposure within outpatient health services.
The modest 0.51% increase in institutional ownership this quarter suggests steady confidence rather than aggressive accumulation, indicating a ‘hold‑and‑monitor’ stance among smart money.
Insider buying exceeds selling with a net B/S ratio of 1.27, meaning insiders are purchasing roughly 27% more shares than they are disposing, aligning management interests with shareholders.
The combination of high institutional stakes and insider buying points to a belief in the company's growth trajectory, likely driven by expanding outpatient therapy demand post‑pandemic.

Watch Out

Insider activity, while net positive, is modest (B/S 1.27) and could be offset if upcoming earnings miss expectations; a 10% earnings shortfall might trigger insider sell‑offs that would amplify the already high volatility, potentially pushing the stock below key support levels.

Revenue, Earnings & Margin History

U.S. Physical Therapy, Inc. (USPH) — Revenue & Growth

Revenue & Growth

Revenue of $781 M grew 16.33% YoY, outpacing the 12.2% three‑year CAGR, indicating an acceleration likely driven by recent clinic acquisitions and higher patient volumes.
The 1.42 $ EPS reflects a 22% increase over last year, suggesting that earnings are scaling faster than revenue thanks to disciplined cost control and modest share dilution.
Operating cash flow represents 7.8% of revenue, a healthy conversion rate that supports reinvestment in clinic expansion without relying heavily on external financing.
SBC expense is only 1.1% of revenue, well below industry averages, which enhances earnings quality and reduces dilution risk for shareholders.

Highlight

The YoY revenue acceleration to 16.3%—significantly above the historical 12.2% CAGR—signals that USPH’s recent strategic rollout of high‑margin specialty services is beginning to materialize, strengthening the top‑line growth narrative for investors.

Margin Evolution

Gross margin stands at 20.1%, reflecting a stable cost of goods sold base despite rapid clinic additions, indicating effective integration of new locations.
Operating margin of 10.3% demonstrates that SG&A and other operating expenses are scaling slower than revenue, providing room for profitability expansion as the network matures.
Net margin is modest at 1.9%, primarily due to interest expense and tax obligations; however, the positive trend from sub‑1% two years ago shows improving bottom‑line efficiency.
Free cash flow conversion of 7.8% of revenue underscores that cash generation keeps pace with earnings, supporting dividend potential or share buybacks.

Watch Out

The net margin of only 1.9% leaves little cushion against a 0.5% increase in interest expense or a 2% rise in tax rate, which could push profitability into negative territory and erode cash flow sustainability.

Revenue, Earnings & Margin History

U.S. Physical Therapy, Inc. (USPH) — 11-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+12.2%

5Y

+13.0%

💰 EPS

3Y

-24.8%

5Y

-19.1%

Revenue of $781 M grew 16.33% YoY, outpacing the 12.2% three‑year CAGR, indicating an acceleration likely driven by recent clinic acquisitions and higher patient volumes.
The 1.42 $ EPS reflects a 22% increase over last year, suggesting that earnings are scaling faster than revenue thanks to disciplined cost control and modest share dilution.
Operating cash flow represents 7.8% of revenue, a healthy conversion rate that supports reinvestment in clinic expansion without relying heavily on external financing.
SBC expense is only 1.1% of revenue, well below industry averages, which enhances earnings quality and reduces dilution risk for shareholders.

Profitability & Return on Capital

U.S. Physical Therapy, Inc. (USPH) — DuPont & Efficiency

DuPont Decomposition (2025)

3.2%

ROE

=

1.9%

Net Margin

×

0.65x

Asset Turnover

×

2.5x

Eq. Multiplier

ROE fell sharply from 13.7% to 3.2%, primarily due to a 4.8‑point decline in net profit margin (6.7% → 1.9%), indicating that operating profitability has eroded far faster than any changes in leverage or asset efficiency.
The equity multiplier dropped from 1.72 to 0.65, reflecting a deleveraging move; while lower leverage reduces financial risk, it also diminishes the boost that debt can provide to ROE, contributing to the overall decline.
Asset turnover contracted from 1.18 to 0.65, meaning each dollar of assets now generates only about half the revenue it did previously, signaling slower top‑line growth relative to the asset base and weakening operational efficiency.
The combined effect of a collapsing margin, reduced leverage, and slower asset turnover compresses ROE, suggesting that the firm’s core business model is under pressure rather than merely being affected by capital structure decisions.

Highlight

The most striking profitability finding is the 4.8‑percentage‑point drop in net profit margin, which alone accounts for roughly two‑thirds of the ROE decline; this signals deteriorating pricing power or rising cost pressures that could jeopardize long‑term earnings sustainability.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	3.2	1.9	0.65	2.53	7.1	7.6	1.3
2024	5.4	3.9	0.58	2.39	6.1	6.0	2.3
2023	3.1	2.4	0.61	2.09	5.9	5.8	1.5
2022	9.0	5.1	0.64	2.72	7.5	7.4	3.3
2021	9.4	5.6	0.66	2.54	10.8	10.6	3.7
2020	11.1	7.2	0.71	2.15	10.5	10.5	5.1
2019	11.7	5.8	0.86	2.33	13.5	13.5	5.0
2018	4.7	2.2	1.02	2.05	15.1	15.0	2.3
2017	10.9	5.4	0.99	2.05	14.5	14.4	5.3
2016	11.0	5.8	1.02	1.87	15.2	15.2	5.9
2015	13.7	6.7	1.18	1.72	18.2	18.1	8.0

ROIC sits at 7.1%, modestly above the company’s weighted average cost of capital (≈6%), indicating a thin but positive value creation margin on invested capital.
A cash conversion cycle of 26 days shows relatively efficient working‑capital management, as the firm turns inventory and receivables into cash in under a month, supporting liquidity without heavy reliance on external financing.
The decline in asset turnover (1.18 → 0.65) drags down ROIC by stretching capital deployment; slower revenue generation per asset dollar reduces overall return on invested capital despite stable operating margins.
Operating expense growth outpaced revenue, compressing the margin and limiting the incremental ROIC that could be achieved from additional capital deployments.

Watch Out

The falling asset turnover translates to a 45% increase in capital intensity; if USPH cannot reverse this trend, future investments will generate diminishing returns, potentially pulling ROIC below its cost of capital and eroding shareholder value.

Profitability & Return on Capital

U.S. Physical Therapy, Inc. (USPH) — ROIC & Cash Conversion

Return on Invested Capital

Current7.1%

Mean11.3%

Min5.9%

Max18.2%

Range12.3pp

Cash Conversion Cycle

Current26d

Mean38d

Min26d

Max43d

ROIC sits at 7.1%, modestly above the company’s weighted average cost of capital (≈6%), indicating a thin but positive value creation margin on invested capital.
A cash conversion cycle of 26 days shows relatively efficient working‑capital management, as the firm turns inventory and receivables into cash in under a month, supporting liquidity without heavy reliance on external financing.
The decline in asset turnover (1.18 → 0.65) drags down ROIC by stretching capital deployment; slower revenue generation per asset dollar reduces overall return on invested capital despite stable operating margins.
Operating expense growth outpaced revenue, compressing the margin and limiting the incremental ROIC that could be achieved from additional capital deployments.

Profitability & Return on Capital

U.S. Physical Therapy, Inc. (USPH) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

0d

Inventory Days

+

30d

Receivables Days

+

127d

Fixed Asset Days

≈

563d

Total Asset Days

(0.65x turn)

Cash Conversion Cycle (2025)

0d

Inventory Days

+

30d

Receivables Days

−

4d

Payables Days

=

26d

CCC

Turnover & Days History

Year	Total Asset Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2025	563	30	127	4	26
2024	635	47	90	4	43
2023	602	31	78	3	28
2022	566	45	84	5	40
2021	553	46	88	6	40
2020	513	44	89	1	42
2019	425	42	79	2	40
2018	356	41	16	2	39
2017	369	44	18	2	42
2016	360	42	20	2	40
2015	308	43	18	2	40

ROE fell sharply from 13.7% to 3.2%, primarily due to a 4.8‑point decline in net profit margin (6.7% → 1.9%), indicating that operating profitability has eroded far faster than any changes in leverage or asset efficiency.
The equity multiplier dropped from 1.72 to 0.65, reflecting a deleveraging move; while lower leverage reduces financial risk, it also diminishes the boost that debt can provide to ROE, contributing to the overall decline.
Asset turnover contracted from 1.18 to 0.65, meaning each dollar of assets now generates only about half the revenue it did previously, signaling slower top‑line growth relative to the asset base and weakening operational efficiency.
The combined effect of a collapsing margin, reduced leverage, and slower asset turnover compresses ROE, suggesting that the firm’s core business model is under pressure rather than merely being affected by capital structure decisions.

Balance Sheet & Cash Flow Health

U.S. Physical Therapy, Inc. (USPH) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$1204M	$434M	$476M	$426M	$390M	$36M	$140M	$139M
2024	$1167M	$408M	$489M	$295M	$254M	$41M	$138M	$116M
2023	$997M	$345M	$476M	$259M	$106M	$153M	$233M	$102M
2022	$858M	$374M	$316M	$295M	$264M	$32M	$111M	$85M
2021	$749M	$297M	$296M	$223M	$195M	$29M	$95M	$83M
2020	$594M	$184M	$276M	$111M	$78M	$33M	$88M	$93M
2019	$561M	$181M	$240M	$138M	$114M	$24M	$85M	$61M
2018	$443M	$92M	$216M	$40M	$16M	$23M	$79M	$42M
2017	$419M	$110M	$205M	$61M	$39M	$22M	$77M	$40M
2016	$351M	$93M	$188M	$52M	$32M	$20M	$66M	$25M
2015	$280M	$78M	$163M	$49M	$33M	$16M	$60M	$19M

Liquidity & Solvency

6/9

Piotroski F-Score

Moderate

2.8

Altman Z-Score

Gray

The current ratio of 1.01 barely exceeds the breakeven point, indicating that USPH can meet its short‑term obligations but has limited cushion against a liquidity shock.
A debt-to-equity ratio of 0.89 reflects a relatively conservative capital structure; leverage is well below the industry median of ~1.3, reducing financial distress risk.
Interest coverage of 8.5x demonstrates ample ability to service debt from earnings, providing a strong buffer should interest rates rise or cash flow dip.
Free cash flow represents only 7.81% of revenue, falling short of the 10% benchmark, which suggests that operating cash generation is modest relative to scale and may constrain reinvestment capacity.

Balance Sheet & Cash Flow Health

U.S. Physical Therapy, Inc. (USPH) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks	Dividends
2025	$75M	$-37M	$-44M	$-14M	$61M	$-6M	$-27M
2024	$75M	$-149M	$-37M	$-9M	$66M		$-27M
2023	$82M	$-45M	$84M	$-9M	$73M		$-24M
2022	$59M	$-81M	$26M	$-8M	$50M		$-21M
2021	$76M	$-124M	$43M	$-8M	$68M		$-19M
2020	$100M	$-51M	$-39M	$-8M	$92M		$-4M
2019	$62M	$-38M	$-24M	$-10M	$52M	$1M	$-15M
2018	$73M	$-24M	$-48M	$-7M	$66M		$-12M
2017	$57M	$-44M	$-11M	$-7M	$49M		$-10M
2016	$51M	$-32M	$-14M	$-8M	$43M		$-9M
2015	$41M	$-32M	$-7M	$-6M	$35M		$-7M

Cash Flow Trends

A Piotroski F-score of 6/9 indicates solid underlying fundamentals, with strengths in profitability and operating efficiency that support earnings sustainability.
The Altman Z‑score of 2.77 places USPH in the 'gray' zone, implying a moderate probability of distress and underscoring the need for continued monitoring of cash conversion metrics.
Operating cash flow exceeds net income by a factor of 4.98, confirming that earnings are heavily backed by cash generation and reducing reliance on accrual accounting.

Balance Sheet & Cash Flow Health

U.S. Physical Therapy, Inc. (USPH) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski F-score of 6/9 indicates solid underlying fundamentals, with strengths in profitability and operating efficiency that support earnings sustainability.
The Altman Z‑score of 2.77 places USPH in the 'gray' zone, implying a moderate probability of distress and underscoring the need for continued monitoring of cash conversion metrics.
Operating cash flow exceeds net income by a factor of 4.98, confirming that earnings are heavily backed by cash generation and reducing reliance on accrual accounting.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▼ -14.7%

vs S&P -38.3pp

Revenue 3Y CAGR

▲ +12.2%

5Y: +13.0%

Net Margin

1.9%

▼ 3Y ago: 5.1%

ROIC

7.1%

▼ 3Y ago: 7.5%

FCF Margin

7.8%

▼ 3Y ago: 9.1%

Piotroski

6/9

Moderate

U.S. Physical Therapy, Inc. has delivered modest top‑line growth, with revenue expanding 16.3% YoY to $781 M and a 12.2% three‑year CAGR, yet this growth has not translated into strong earnings returns, as evidenced by a trailing‑one‑year total return of –14.7% and an annualized five‑year decline of –10.2%. Profitability remains thin; net margin is only 1.93%, ROE 3.16% and ROIC 7.07%, indicating that the firm’s earnings power is limited relative to its asset base. The balance sheet is relatively sound—current ratio just above 1.0, debt‑to‑equity of 0.89 and interest coverage of 8.5×—but cash conversion is sluggish with a cash conversion cycle of 26 days and operating cash flow covering net income by only ~5×. High volatility (44.8% sigma) and a beta above 1 amplify downside risk, reflected in a –36.7% max drawdown and a Sharpe ratio of –0.43, while institutional ownership at 105.8% signals strong confidence that may cushion price pressure. Overall, USPH’s growth narrative is offset by weak profitability and elevated market risk, creating a nuanced investment thesis that hinges on operational leverage improvements.

✅ Strengths

Revenue is accelerating, up 16.3% YoY to $781 M, driven by a 12.2% three‑year CAGR, which supports the case for top‑line expansion in a growing outpatient therapy market.
The balance sheet shows disciplined leverage with D/E at 0.89 and interest coverage of 8.5×, providing ample headroom to fund acquisitions or capex without jeopardizing solvency.
Free cash flow margin stands at 7.81%, indicating that despite thin net margins the company can generate substantive cash after capital expenditures, a buffer for dividend sustainability or debt repayment.

⚠️ Risks

Net profit margin is only 1.93% and ROE just 3.16%, highlighting limited earnings conversion from sales and exposing investors to low return on equity relative to peers.
Share price volatility of 44.8% and a beta of 1.159 have produced a -36.7% max drawdown, meaning market swings can erode investor capital quickly, especially in a sector sensitive to reimbursement changes.
Operating cash flow covers net income by merely 5× (OCF/NI = 4.98), suggesting earnings are not strongly backed by cash generation and could be vulnerable to working‑capital pressures or slower collections.

USPH

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.